Bone Therapeutics treats 12 patients without safety concerns in ALLOB phase IIA spinal fusion trial
Bone Therapeutics has now treated 12 patients in its ALLOB® Phase IIA spinal fusion trial without any safety concerns. The trial is progressing quickly with only one more patient cohort of four patients to treat. Safety and efficacy of this treatment is assessed over 12 months, using clinical and radiological evaluations. The trial is currently running in eight centres across Belgium. Today, the procedure has been performed in 12 patients without any complications or safety issues.
Click on this link for more information.